Abstract: Disclosed are compositions and methods for related to echogenic contrast agents. Also disclosed are methods and compositions for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for producing a medical image of a tissue. Also disclosed are methods of monitoring the progression of eosinophilic esophagitis in a subject before, during, and after treatment.

Abstract: Disclosed are devices, compositions, and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.

Abstract: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

Abstract: The use of a eosinophil secondary granules basic protein and any functional fragments thereof, and preferably, the use of Major Basic Protein (MBP) purified from eosinophils, as a natural heparanase inhibitor. Also, methods for the inhibition of the catalytic activity of heparanase using MBP, and to methods and compositions for the treatment of heparanase associated pathologic disorders. These methods and composition are particularly useful for the treatment of angiogenesis, tumor formation, tumor progression or tumor metastasis.